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a b s t r a c t
Introduction: Cardiovascular disorders are the major cause of mortality and morbidity
globally as well as in India. In India, where resources are limited and majority of patients
pay out of their own pocket, thrombolysis is still done for majority of STEMI cases.
Case Scenario: A 48-year-old male patient, nonhypertensive and nondiabetic, came to the ER
with history of retrosternal chest pain suggestive of angina at rest. An Electrocardiogram
(ECG) revealed ST-segment elevation in the anterior leads. Patientwas diagnosedwith Acute
STEMI and thrombolysis was initiated with STK. The following day, the patient complained
of pain in his left groin. On examination, there was a swelling and tenderness in left lower
abdomen and inability to extend the hip. A CT scan was done, which showed Psoas muscle
hematoma.
Conclusion: Spontaneous bleed into psoasmuscle is a very rare complication of thrombolysis
that may require surgical exploration.
# 2015 Cardiological Society of India. Published by Elsevier B.V. This is an open access
article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. IntroductionCardiovascular disorders are the major cause of mortality and
morbidity globally as well as in India. The incidence of
Cardiovascular Disease (CVD) in India has risen from 7% in
1970 to 32% in 2011.1 Coronary Artery Disease (CAD) is
prevalent among 8–10% of urban and 3–4% of rural population* Corresponding author.
E-mail address: sunil167@yahoo.com (B.S. Abhishek).
http://dx.doi.org/10.1016/j.ihj.2015.09.031
0019-4832/# 2015 Cardiological Society of India. Published by Elsevier
(http://creativecommons.org/licenses/by-nc-nd/4.0/).and it accounts for close to 1.5 million deaths per year.1
Primary percutaneous intervention, when performed in a
timely fashion, is the reperfusion therapy of choice in patients
presenting with Acute ST-segment Elevation Myocardial
Infarction (STEMI).2–7 In India, where resources are limited
and majority of patients pay out of their own pocket,
thrombolysis is still done for majority of STEMI cases.8
Fibrin-speciﬁc ﬁbrinolytic agent is the preferred agent, butB.V. This is an open access article under the CC BY-NC-ND license
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The most dreaded complication of STK is Intracerebral
Hemorrhage (ICH), which usually occurs in less than 1% cases.
Other common complications are allergic reactions and
hypotension, which usually respond to steroids and ﬂuid
replacement, respectively. Noncerebral bleeding is also a
common complication, usually from the puncture sites and
mucosa. Here we report a rare case of spontaneous psoas
hematoma after thrombolytic therapy with STK infusion.
2. Case scenarioA 48-year-oldmale patient, nonhypertensive and nondiabetic,
came to the ER with history of retrosternal chest pain
suggestive of angina at rest. Patient used to chew tobacco
and consume alcohol occasionally. An electrocardiogram
(ECG) revealed ST-segment elevation in the anterior leads
(Fig. 1). There was regional wall motion abnormality noted in
the anterior wall, in the 2D echocardiogram. Patient was
diagnosed with Acute STEMI and thrombolysis was initiated
with STK. Patient was started on standard Acute Coronary
Syndrome (ACS) management with antiplatelets, nitrates,
beta-blockers, and statins. His pain subsided and the ECG at
90 min post-STK showed good resolution of more than 70%
(Fig. 2). The following day, the patient complained of pain in
his left groin. On examination, there was a swelling and
tenderness in left lower abdomen and inability to extend the
hip.
A screening ultrasound was done, which was normal. A CT
scan was done, which showed Psoas muscle hematoma
(Fig. 3). The patient's Hemoglobin (Hb) fell from 16 g/dL to
8.5 g/dL. Patient was managed conservatively; heparin and
antiplatelets were stopped. The patient improved symptom-
atically and the Hb increased to 11.6 g/dL, no transfusion blood
or blood products were administered.[(Fig._1)TD$FIG]
Fig. 1 – ECG at p3. DiscussionStreptokinase is a protein, and a single-chain polypeptide,
derived from beta-hemolytic streptococci cultures. It com-
bines with pro-activator plasminogen and converts inactive
plasminogen into plasmin.9,10 High dose of STK is needed to
neutralize the anti-streptococci antibodies. STK produces a
profound hypocoagulable state; despite this, the bleeding
chances are rather rare. The ﬁrst large-scale thrombolytic trial
was GISSI-1,11 which showed that themortality at 21 days was
8–10% in patients thrombolyzed compared to 15%mortality in
the group not thrombolyzed. Similar results were seen in ISIS-
2 trial.12
Major adverse effects of STK are Allergic reactions,
Hypotension, and Bleeding. Since STK is a protein, it is
antigenic. Though major anaphylaxis reactions are seen in
<0.5% of cases, minor reactions like itching are seen in 10% of
the cases. The biological efﬁcacy does not seem to be
decreased when the patient develops allergic reactions.
Anti-Strep antibodies can be found in the body for 7.5 years.13
STK is not given if the patient has been administered with it
within the past 6 months. Hypotension is the other common
side effect usually seen when STK is infused at a dose higher
than 500 U/kg/min. This usually responds to decrease in the
speed of infusion. If it does not, then ﬂuids can be infused; in
resistant cases, inonotropic support can be used.
Bleeding, including major and minor, from any site is
usually seen in around 11% of the cases that are thrombolyzed.
Gastrointestinal tract is themost common site of spontaneous
bleed. 3–4% of the patients will have minor bleeds from
puncture sites. Major bleeding like Intracerebral Hemorrhage
is usually seen in <1% of cases, and after 70 years of age the
risk increases to 1.67%.14,15 Hemorrhage can also occur into
spleen, mediastinum, liver, intraspinally, tongue, and rec-
tum.16–20 There has been only one case report in literature tillresentation.
[(Fig._2)TD$FIG]
Fig. 2 – Post-streptokinase (STK) administration; ECG showing good resolution.
[(Fig._3)TD$FIG]
Fig. 3 – Showing bulky psoas muscle, with collection on the
left side.
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) s 1 8 – s 2 1S20now describing spontaneous psoas hematoma post-STK
infusion.21
4. ConclusionSTK still commonly used for the treatment of AMI patients.
Spontaneousbleedintopsoasmuscle isaveryrarecomplication
of thrombolysis. Itmust be consideredwhen patient complains
of pain in the groin that increased in intensity on extending the
hip.AsFemoralnervepasses throughthePsoasmuscle, thishas
the potential of causing entrapment mononeuropathy. Since
the area is retroperitoneal and cannot be reached easily, this
complicationmust always be kept inmind and patientmust be
evaluated using imaging techniques. Ultrasound can be a good
screening test, but to conﬁrm, the diagnosis Computer
Tomography (CT) or Magnetic Resonance Imaging (MRI) isneeded. Majority of cases can be managed conservatively by
stopping antithrombotics and antiplatelets. If the patient has
hemodynamic instability, transfusion is needed. In severe
cases, decompressive surgery may be considered.
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